Continue Jardiance - These Lab Values Are Expected and Not Concerning
Your patient's labs show expected physiologic changes from Jardiance (empagliflozin) and do not require discontinuation or dose adjustment. The eGFR of 52 mL/min/1.73 m² is well above the safety threshold, the creatinine increase is mild, and the potassium of 3.4 mmol/L, while slightly low, is not in the danger zone.
Why These Values Are Acceptable
eGFR of 52 mL/min/1.73 m²
- Jardiance can be safely continued down to eGFR ≥20 mL/min/1.73 m² for cardiovascular and kidney protection 1, 2
- The FDA label confirms no dose adjustment is needed with eGFR ≥30 mL/min/1.73 m² for heart failure indications, and studies enrolled patients with eGFR ≥20 mL/min/1.73 m² 3
- An initial eGFR decline of 2-3 mL/min/1.73 m² is expected and beneficial - this represents hemodynamic adjustment, not kidney injury 4, 5, 6
- In EMPEROR-Reduced, patients with early eGFR decline actually had no increased risk of adverse kidney outcomes compared to those without decline 4
Creatinine 1.04 mg/dL
- This mild elevation is consistent with the expected hemodynamic effect of SGLT2 inhibitors
- The FDA label specifically notes that risks of renal impairment increase with worsening function, but your patient at eGFR 52 is in a safe range 3
- Do not discontinue for modest creatinine increases - the long-term kidney protection outweighs this transient change 7, 4
Potassium 3.4 mmol/L
- While slightly below normal (typically 3.5-5.0 mmol/L), this is not severe hypokalemia
- Empagliflozin actually reduces hyperkalemia risk rather than causing problematic hypokalemia 8, 9
- In EMPEROR-Pooled, empagliflozin reduced hyperkalemia events without significantly increasing hypokalaemia 8
- The 2012 ESC guidelines note concern for K+ ≤3.5 mmol/L with diuretics 10, but your patient is just at this threshold
What You Should Do
Immediate Actions
- Continue Jardiance at current dose - do not reduce or discontinue
- Monitor potassium - if the patient is on loop diuretics, consider:
- Reducing diuretic dose if euvolemic
- Adding potassium supplementation if K+ drops further
- Checking magnesium (hypomagnesemia can cause refractory hypokalemia)
Follow-Up Monitoring
- Recheck labs in 2-4 weeks to ensure:
- Creatinine stabilizes (expect it may stay slightly elevated - this is protective)
- Potassium remains >3.0 mmol/L
- No signs of volume depletion
- Long-term: Monitor eGFR every 3-6 months as you would for any CKD patient
Common Pitfalls to Avoid
Do not stop Jardiance for mild eGFR decline - This is the most critical point. The initial dip in eGFR represents beneficial hemodynamic changes (reduced intraglomerular pressure), not kidney damage 4, 5. Stopping the medication deprives the patient of proven cardiovascular and kidney protection.
Do not confuse hemodynamic changes with acute kidney injury - True AKI would show muddy brown casts on urinalysis and occur in the context of hypotension, sepsis, or other insults 7. Your patient's changes are physiologic.
Do not over-treat mild hypokalemia - K+ of 3.4 mmol/L requires monitoring but not aggressive repletion unless symptomatic or the patient has arrhythmia risk factors.
The Evidence Supporting Continuation
The 2022 ADA/KDIGO consensus explicitly states: "Once initiated, the SGLT2i can be continued at lower levels of eGFR" 1. The 2025 ADA Standards recommend SGLT2 inhibitors for patients with eGFR ≥20 mL/min/1.73 m² 2. Your patient at eGFR 52 has substantial margin above this threshold.
In EMPEROR-Reduced, empagliflozin showed consistent benefit across the entire range of kidney function studied, including patients with baseline eGFR as low as 20 mL/min/1.73 m² 6. The cardiovascular and kidney benefits are maintained regardless of the initial eGFR dip 4.
Regarding hyperkalemia concerns with SGLT2 inhibitors: empagliflozin actually reduces hyperkalemia risk by approximately 18% (HR 0.82) 8, making it safer to continue other guideline-directed medical therapy like ACE inhibitors or mineralocorticoid receptor antagonists.